CCCC (C4 Therapeutics) Other Long Term Assets: $7.93 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CCCC C4 Therapeutics Inc CCCC
49 GF Score
Price $4.12
GF Value $2.05
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is C4 Therapeutics Other Long Term Assets?

C4 Therapeutics CCCC +2.50% 49 Other Long Term Assets is $7.93 Mil as of Jun. 2026. GuruFocus rates CCCC with a GF Score™ of 49/100 and a GF Value™ of $2.05 (Significantly Overvalued). The stock has 7 warning signs investors should review.

C4 Therapeutics's other long-term assets for the quarter that ended in Jun. 2026 was $7.93 Mil.

C4 Therapeutics's quarterly other long-term assets increased from Dec. 2025 ($7.13 Mil) to Mar. 2026 ($7.31 Mil) and increased from Mar. 2026 ($7.31 Mil) to Jun. 2026 ($7.93 Mil).

C4 Therapeutics's annual other long-term assets declined from Dec. 2023 ($6.17 Mil) to Dec. 2024 ($6.10 Mil) but then increased from Dec. 2024 ($6.10 Mil) to Dec. 2025 ($7.13 Mil).

C4 Therapeutics Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for C4 Therapeutics's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

C4 Therapeutics Other Long Term Assets Chart

C4 Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long Term Assets
Get a 7-Day Free Trial 3.82 4.80 6.17 6.10 7.13

C4 Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.62 3.65 7.13 7.31 7.93
CCCC
49GF Score
C4 Therapeutics Inc CCCC
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

C4 Therapeutics Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of $7.93 Mil mean?
C4 Therapeutics (CCCC) has a Other Long Term Assets of $7.93 Mil as of Jun. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on C4 Therapeutics and its competitors.
Is C4 Therapeutics' Other Long Term Assets too high?
C4 Therapeutics' current Other Long Term Assets is $7.93 Mil. Overall, C4 Therapeutics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does C4 Therapeutics' Other Long Term Assets compare to CMPX and AVIR?
C4 Therapeutics' Other Long Term Assets of $7.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Biotechnology company?
A good Other Long Term Assets depends on the Biotechnology industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on C4 Therapeutics and its competitors. C4 Therapeutics's current Other Long Term Assets is $7.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C4 Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, C4 Therapeutics (CCCC) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.05, compared to a current price of $4.12 — trading 100.7% above its estimated fair value. The current Other Long Term Assets is $7.93 Mil. C4 Therapeutics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For C4 Therapeutics (CCCC), the current Other Long Term Assets is $7.93 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is C4 Therapeutics (CCCC) Overvalued in 2026?

Based on GuruFocus' analysis, C4 Therapeutics stock appears to be overvalued. The current stock price of $4.12 is trading 100.7% above its estimated GF Value™ of $2.05. GuruFocus considers C4 Therapeutics to be Significantly Overvalued.

Key valuation signals for CCCC:

  • Other Long Term Assets: $7.93 Mil
  • GF Value™: $2.05 vs. price of $4.12 (100.7% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the CCCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

C4 Therapeutics Business Description

Address 490 Arsenal Way, Suite 120, Watertown, MA, USA, 02472
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
49GF Score

Get the complete analysis for CCCC

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.12
Price
$2.05
GF Value